Savara Company profile
About Savara Inc
Savara Inc. is a clinical stage company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Savara Inc revenues decreased from $256K to $0K. Net loss decreased 12% to $31.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 13% to $20.4M (expense), Stock-based Compensation in SGA decrease of 51% to $1.5M (expense), Selling.
Equity composition
Common Stock $.001 Par, 12/11, 500M auth., 47,715,709 issd. Insiders own approx. 0.08% . IPO: N/A. PO: 11/02/06, 14,545,000 shs. @ $2.75 per share by ThinkEquity Partners LLC & Fortis Securities LLC. 04/10, 1-for-25 reverse split.
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)